Cardiac testing company CardiNor AS has announced that it has signed an exclusive agreement with IBL-America for sales of the CardiNor Secretoneurin ELISA test in the USA.
By initially targeting research institutes, clinical research organisations and pharmaceutical companies, the company is aiming to raise awareness of the frontline biomarker, ultimately paving the way for future commercialisation upon US regulatory clearance.
Secretoneurin (SN) is a biomarker shown to be associated with biological processes linked to heart cell calcium handling a key mechanism in the regulation of arrhythmia and has been described as the “missing link biomarker” in cardiovascular disease risk assessment.
This biological function may explain why SN has been shown to be an independent and strong predictor of mortality in all major patient cohorts tested, including patients with ventricular arrhythmia, acute heart failure, and acute respiratory failure patients with cardiovascular disease and severe sepsis, CardioNor said in a press release.
“Cardiovascular disease research is a key market for IBL-America and CardiNor’s Secretoneurin ELISA test is an excellent addition to our portfolio. We are convinced our customers will find it an invaluable research tool,” says Mark Kowal, president and CEO, IBL-America.
“We are delighted to work with IBL-America, a company with extensive experience in distributing high quality laboratory research and clinical products in the USA. IBL has a very strong position with the major reference laboratories and with their own CLIA laboratory they can support our planned US regulatory activities. Our test is generating a great deal of interest worldwide and signing this deal with IBL-America will enable us to increase our presence in the important US research market,” added Dag Christiansen, CEO of CardiNor.
The CardiNor SN assay is based on work by Torbjørn Omland and his research group at Akershus University Hospital (Nordbyhagen, Norway).